{"id":"https://openalex.org/W2601828615","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.4090","title":"Association of progression-free survival with overall survival (OS) in patients (pts) with neuroendocrine tumor (NET) treated with somatostatin analogs.","display_name":"Association of progression-free survival with overall survival (OS) in patients (pts) with neuroendocrine tumor (NET) treated with somatostatin analogs.","publication_year":2015,"publication_date":"2015-05-20","ids":{"openalex":"https://openalex.org/W2601828615","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.4090","mag":"2601828615"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2015.33.15_suppl.4090","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.4090","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.4090","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028280842","display_name":"Monica Ter\u2010Minassian","orcid":"https://orcid.org/0000-0002-9497-2585","observed_orcids":["https://orcid.org/0000-0002-9497-2585"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Monica Ter-Minassian","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028521869","display_name":"Nichole V. Brooks","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nichole V Brooks","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028547202","display_name":"Lauren K. Brais","orcid":"https://orcid.org/0000-0003-1069-0407","observed_orcids":["https://orcid.org/0000-0003-1069-0407"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lauren K Brais","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114950423","display_name":"Jennifer Ang Chan","orcid":"https://orcid.org/0000-0003-2523-9598","observed_orcids":["https://orcid.org/0000-0003-2523-9598"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer A. Chan","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091331939","display_name":"David C. Christiani","orcid":"https://orcid.org/0000-0002-0301-0242","observed_orcids":["https://orcid.org/0000-0002-0301-0242"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David C. Christiani","raw_affiliation_strings":["Harvard School of Public Health, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Harvard School of Public Health, Boston, MA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030660111","display_name":"Xihong Lin","orcid":"https://orcid.org/0000-0001-7067-7752","observed_orcids":["https://orcid.org/0000-0001-7067-7752"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xihong Lin","raw_affiliation_strings":["Harvard School of Public Health, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Harvard School of Public Health, Boston, MA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055616921","display_name":"Sylvie Gabriel","orcid":"https://orcid.org/0000-0002-7525-4510","observed_orcids":["https://orcid.org/0000-0002-7525-4510"]},"institutions":[{"id":"https://openalex.org/I183367347","display_name":"Ipsen (France)","ror":"https://ror.org/00d801g55","country_code":"FR","type":"company","lineage":["https://openalex.org/I183367347"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Sylvie Gabriel","raw_affiliation_strings":["Ipsen Pharma, Boulougne-Billancourt, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ipsen Pharma, Boulougne-Billancourt, France","institution_ids":["https://openalex.org/I183367347"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102892969","display_name":"J\u00e9r\u00f4me Dinet","orcid":"https://orcid.org/0000-0002-6890-3551","observed_orcids":["https://orcid.org/0000-0002-6890-3551"]},"institutions":[{"id":"https://openalex.org/I183367347","display_name":"Ipsen (France)","ror":"https://ror.org/00d801g55","country_code":"FR","type":"company","lineage":["https://openalex.org/I183367347"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jerome Dinet","raw_affiliation_strings":["Ipsen Pharma, Boulougne-Billancourt, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ipsen Pharma, Boulougne-Billancourt, France","institution_ids":["https://openalex.org/I183367347"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5017947396","display_name":"Matthew H. Kulke","orcid":"https://orcid.org/0000-0001-8556-3977","observed_orcids":["https://orcid.org/0000-0001-8556-3977"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew H. Kulke","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"33","issue":"15_suppl","first_page":"4090","last_page":"4090"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10832","display_name":"Pituitary Gland Disorders and Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neuroendocrine-tumors","display_name":"neuroendocrine tumors","score":0.9520000219345093},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8100000023841858},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9980000257492065},{"id":"https://openalex.org/keywords/somatostatin-analogs","display_name":"somatostatin analogues","score":0.9909999966621399},{"id":"https://openalex.org/keywords/metastatic-neuroendocrine-tumors","display_name":"metastatic neuroendocrine tumors","score":0.9210000038146973},{"id":"https://openalex.org/keywords/tumor-progression","display_name":"tumor progression","score":0.652999997138977},{"id":"https://openalex.org/keywords/small-intestinal-neuroendocrine-tumors","display_name":"small bowel neuroendocrine tumors","score":0.7870000004768372},{"id":"https://openalex.org/keywords/pancreatic-neuroendocrine-tumors","display_name":"pancreatic neuroendocrine tumors","score":1.0},{"id":"https://openalex.org/keywords/landmark-analysis","display_name":"landmark analysis","score":0.6899999976158142},{"id":"https://openalex.org/keywords/survival-after-progression","display_name":"survival after progression","score":0.3930000066757202},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.453000009059906}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8705657124519348},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.7015938758850098},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6397467851638794},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6278391480445862},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.5790930986404419},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.5646257996559143},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5346500277519226},{"id":"https://openalex.org/C2779066768","wikidata":"https://www.wikidata.org/wiki/Q1981276","display_name":"Neuroendocrine tumors","level":2,"score":0.504963219165802},{"id":"https://openalex.org/C2779256057","wikidata":"https://www.wikidata.org/wiki/Q16909647","display_name":"Tumor progression","level":3,"score":0.4876050055027008},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.4712439179420471},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.44672146439552307},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.4458337128162384},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.4199608564376831},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.39281508326530457},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.3394826054573059},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.29148975014686584}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2015.33.15_suppl.4090","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.4090","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.4090","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2587129213","https://openalex.org/W2536049310","https://openalex.org/W3157038552","https://openalex.org/W3111770786","https://openalex.org/W2726607445","https://openalex.org/W1977347411","https://openalex.org/W2520866608","https://openalex.org/W3035273049","https://openalex.org/W4404961587","https://openalex.org/W4387826097"],"abstract_inverted_index":{"4090":[0],"Background:":[1],"Progression-free":[2],"survival":[3],"(PFS)":[4],"is":[5,18,22],"commonly":[6],"used":[7,85,125],"as":[8,145,160,274],"a":[9,33,52,86],"primary":[10],"endpoint":[11,276],"in":[12,32,57,92,277,284],"NET":[13,278,285],"clinical":[14,279],"trials.":[15,280],"Whether":[16],"PFS":[17,29,142,202,241,262,273,281],"associated":[19,204,264],"with":[20,39,42,65,94,117,132,205,242,256,260,265,288],"OS":[21,31,91,129,157,206,226,243,283],"uncertain.":[23],"We":[24,47,84],"assessed":[25,116],"the":[26,166,175,208,270],"association":[27,239],"between":[28],"and":[30,73,187,194,212,282,374],"large":[34],"observational":[35,54,252],"cohort":[36,253],"of":[37,147,152,162,171,240,254,272],"pts":[38,50,93,131,192,255],"NETs":[40,67,186,258],"treated":[41,259,287],"somatostatin":[43],"analogs":[44],"(SSA).":[45],"Methods:":[46],"enrolled":[48],"1330":[49],"to":[51,89,106,126,150,169],"prospective":[53],"study,":[55],"beginning":[56],"2003.":[58],"Of":[59,174],"these":[60],"pts,":[61,177],"we":[62],"identified":[63],"440":[64,176],"metastatic":[66,257],"who":[68,217,230],"had":[69,179,184,223],"received":[70],"single-agent":[71],"SSA":[72,289],"were":[74,115,124],"evaluable":[75],"for":[76,130,367],"tumor":[77,247,370,372],"progression,":[78],"based":[79],"on":[80],"medical":[81],"record":[82],"review.":[83],"landmark":[87,140,167,221],"analysis":[88],"assess":[90],"progression":[95,154],"(PD)":[96],"or":[97,155],"without":[98,136],"PD":[99,133,137,296,299,302,304],"at":[100,138,207],"6":[101,105,310],"month":[102,214],"intervals,":[103],"from":[104],"24":[107,213,352],"months":[108],"after":[109],"treatment":[110,148,163],"initiation.":[111],"Adjusted":[112,307],"hazard":[113],"ratios":[114],"Cox":[118],"proportional":[119],"hazards":[120],"models.":[121],"Kaplan-Meier":[122],"estimates":[123],"calculate":[127],"median":[128,225],"vs.":[134],"those":[135,216,229],"each":[139,220],"time.":[141],"was":[143,158,199,203,244,263],"defined":[144,159],"time":[146,151,161,168,170,222,294],"initiation":[149,164],"first":[153],"death.":[156,172],"plus":[165],"Results:":[173],"224":[178],"small":[180],"bowel":[181],"NETs,":[182],"93":[183],"pancreatic":[185],"123":[188],"other":[189],"NETs.":[190],"311":[191],"progressed":[193,218],"215":[195],"died.":[196],"Median":[197],"follow-up":[198],"7.6":[200],"yrs.":[201],"6,":[209],"12,":[210],"18,":[211],"landmarks:":[215],"by":[219],"shorter":[224],"times":[227],"than":[228],"did":[231],"not":[232],"progress":[233],"(see":[234],"table).":[235],"A":[236],"trend":[237],"suggesting":[238],"seen":[245],"across":[246],"subgroups.":[248],"Conclusions:":[249],"In":[250],"this":[251],"SSA,":[261],"OS.":[266],"Our":[267],"findings":[268],"support":[269],"use":[271],"an":[275],"patients":[286],"(N":[290],"=":[291,322,336,350,364],"440).":[292],"Landmark":[293],"No":[295,298],"(N)":[297,303],"(Median":[300,305],"OS)":[301,306],"HRa":[308],"(95%CI)":[309],"mo":[311,325,339,353],"327":[312],"7.52":[313],"yrs":[314,317,328,331,342,345,356,359],"107":[315],"3.62":[316],"1.72":[318],"(1.25,":[319,347],"2.37),":[320],"p":[321,335,349,363],"0.0009":[323],"12":[324],"249":[326],"7.02":[327],"169":[329],"4.71":[330],"1.47":[332],"(1.07,":[333,361],"2.00),":[334],"0.017":[337],"18":[338],"181":[340],"7.10":[341],"220":[343],"3.97":[344],"1.77":[346],"2.51),":[348],"0.0014":[351],"147":[354],"6.79":[355],"219":[357],"4.21":[358],"1.58":[360],"2.32),":[362],"0.02":[365],"aAdjusted":[366],"age,":[368],"gender,":[369],"grade,":[371],"origin,":[373],"post-progression":[375],"treatment.":[376]},"counts_by_year":[{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2017-04-07T00:00:00"}